A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Public ClinicalTrials.gov record NCT07012395. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
Study identification
- NCT ID
- NCT07012395
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Spyre Therapeutics, Inc.
- Industry
- Enrollment
- 645 participants
Conditions and interventions
Interventions
- Placebo Other
- SPY001 Drug
- SPY002 Drug
- SPY003 Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 26, 2025
- Primary completion
- May 31, 2026
- Completion
- Feb 29, 2028
- Last update posted
- Apr 20, 2026
2025 – 2028
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 024 | Canoga Park | California | 91304 | Recruiting |
| Site 023 | La Jolla | California | 92037 | Recruiting |
| Site 012 | Lancaster | California | 93534 | Recruiting |
| Site 033 | Colorado Springs | Colorado | 91304 | Recruiting |
| Site 007 | Kissimmee | Florida | 34741 | Recruiting |
| 029 | Miami | Florida | 33165 | Recruiting |
| Site 006 | Kansas City | Kansas | 66160 | Recruiting |
| Site 035 | Marrero | Louisiana | 70072 | Recruiting |
| Site 011 | Glen Burnie | Maryland | 21061 | Recruiting |
| Site 003 | Boston | Massachusetts | 02114 | Recruiting |
| Site 028 | Rochester | Minnesota | 55905 | Recruiting |
| Site 037 | New York | New York | 10065 | Recruiting |
| 040 | Chapel Hill | North Carolina | 27599 | Recruiting |
| Site 041 | Durham | North Carolina | 27710 | Recruiting |
| Site 016 | Winston-Salem | North Carolina | 27103 | Recruiting |
| Site 025 | Providence | Rhode Island | 02904 | Recruiting |
| Site 017 | Kingsport | Tennessee | 37663 | Recruiting |
| Site 013 | Cedar Park | Texas | 78613 | Recruiting |
| Site 005 | Garland | Texas | 75246 | Recruiting |
| Site 002 | San Antonio | Texas | 78229 | Recruiting |
| Site 008 | Southlake | Texas | 76092 | Recruiting |
| Site 009 | Webster | Texas | 77598 | Recruiting |
| Site 019 | Tacoma | Washington | 98405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 139 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07012395, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07012395 live on ClinicalTrials.gov.